# US 9,433,668 B2 · Prostate cancer vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,433,668 B2
- Document ID: US9433668B2
- Status: Granted
- Kind: B2
- Application number: 14/614,137
- Filed: 2015-02-04
- Published: 2015-10-29
- Granted: 2016-09-06
- Earliest claimed: 2006-09-01
- Assignees: Wisconsin Alumni Research Foundation
- Applicants: Wisconsin Alumni Research Foundation
- Inventors: Douglas G. McNeel; Brian M. Olson
- Web page: https://patentgrep.com/patent/US9433668B2

## CPC

- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 39/001102: {Receptors, cell surface antigens or cell surface determinants}
- A61K 39/001193: {Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR}
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/117: Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- C12N 15/85: for animal cells
- G01N 33/56972: {White blood cells}
- G01N 33/57555: of the prostate
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/585: {wherein the target is cancer}
- A61K 2039/884: {prostate}
- C12N 2800/107: for mammalian
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Androgen receptor-based vaccines for eliciting an immune reaction in vivo against cells expressing androgen receptor are disclosed. The vaccines are useful in the treatment of prostate cancer. Also disclosed are methods for inducing immune reaction to androgen receptor or treating prostate cancer in a mammal, using the vaccines and pharmaceutical compositions comprising the vaccines.

## Claims

### Claim 1

A method for treating prostate cancer in a human patient having prostate cancer, the method comprising the step of:
administering to the human patient an effective amount of a DNA vaccine comprising a polynucleotide operatively linked to a transcriptional regulatory element,
wherein the polynucleotide encodes a fragment of a mammalian androgen receptor consisting essentially of the ligand-binding domain of the receptor, the ligand-binding domain fragment selected from the group consisting of (i) SEQ ID NO:9, (ii) SEQ ID NO:10, (iii) SEQ ID NO:11, and (iv) SEQ ID NO:12,
under conditions such that said prostate cancer is treated.

### Claim 2 (depends on 1)

The method of claim 1, wherein said DNA vaccine is administered in a pharmaceutically acceptable carrier.

### Claim 3 (depends on 1)

The method of claim 1, wherein the DNA vaccine is a plasmid vector that comprises:
(a) a backbone of pNGVL3;
(b) the polynucleotide operably positioned in the backbone; and optionally
(c) an immunostimulatory sequence (ISS) motif.

### Claim 4 (depends on 3)

The method of claim 3, wherein:
(a) the polynucleotide is operatively linked to a CMV promoter and to a CMV intron A for enhancing expression of the polynucleotide; and optionally
(b) the optional immunostimulatory sequence (ISS) motif comprises at least one copy of 5′-GTCGTT-3′.

### Claim 5 (depends on 1)

The method of claim 1, wherein the fragment is a fragment of a human androgen receptor.

### Claim 6 (depends on 1)

The method of claim 1, wherein the vaccine is administered with a suitable amount of GM-CSF.